Drug Discovery

Study suggests epigenetic protein as new therapeutic target in AML

A new study in the UK has shown that EZH2, an epigenetic protein, can potentially be a new therapeutic target for the treatment of acute myeloid leukemia (AML).

Evotec, GARDP partner to tackle antimicrobial resistance threat

German biotech company Evotec has entered into a partnership with The Global Antibiotic Research and Development Partnership (GARDP) to discover antibiotics for the treatment of drug-resistant bacterial infections.

Ono enters into research collaboration agreement with twoXAR

Ono Pharmaceutical and twoXAR have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.

Imara closes $63m Series B cross-over financing

Imara, a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and other hemoglobinopathies, announced the closing of an oversubscribed $63 million Series B cross-over financing.

Merck KGaA to use Iktos AI technology across three drug discovery projects

Merck KGaA, Darmstadt, Germany, is collaborating with Iktos, a French start-up company specialized in artificial intelligence (AI) for new drug design, to further accelerate its drug discovery capabilities.

Seres, AstraZeneca to collaborate on microbiome immuno-oncology

US-based Seres Therapeutics and AstraZeneca have entered into a three-year research collaboration, which will focus on further understanding the potential of microbiome therapeutics in supplementing immuno-oncology treatment.

Clinical stage biotech company InventisBio closes $70m Series C financing

InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019.

TaiwanJ Pharmaceuticals out-licenses liver drug candidate in Asia

TaiwanJ Pharmaceuticals has signed a $26 million contract with Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia.

GTx, Oncternal Therapeutics sign merger deal to create new clinical-stage oncology firm

Biopharmaceutical firm GTx has entered into a merger agreement with clinical-stage biotechnology firm Oncternal Therapeutics to create a new a publicly-traded and clinical-stage oncology company.